Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (257)	1/31/2003 1:14:01 PM
From: JMarcus	Read Replies (1) \| Respond to of 3722

On 7/31/02 BPUR submitted an electronic BLA to the FDA seeking regulatory clearance to market Hemopure in the United States for the treatment of acute anemia in adult patients undergoing orthopedic surgery. On 10/1/02 BPUR announced that the FDA had accepted the BLA for review. When would you expect FDA's verdict? Late July or early October? That verdict will determine the destiny of BPUR -- not sales to vets or sales to hospitals in South Africa. Marc

To: Jibacoa who wrote (257)	2/13/2003 11:05:15 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

BPUR Is up 20.18% on volume of 360KK (about 3x its daily average), after announcing that it will receive $4M authorized by Congress, to conduct clinical trials of its Hemopure, in trauma situations. BPUR is trying to obtain FDA's approval to use Hemopure in trauma patients, by proving that it can remain stable for long periods of time and elevated temperatures.Hemopure would represent the first artificial blood substitute product. The stock traded earlier at 4.10 (above the Feb.3 H of 3.99) It has to close above that level before it can test the Dec.27 H at 4.25 and the Hs of Nov. & Oct. at 5.75 & 6.40 respectively.<g> siliconinvestor.com Bernard